Ticker LaunchReverse merger · Completed · IMA
Inmagene Biopharmaceuticals
Reverse merger with Ikena Oncology, Inc. (IKNA)
Inmagene Biopharmaceuticals merged into Ikena Oncology, Inc. (IKNA), a Nasdaq-listed oncology biotech seeking a strategic partner, in a reverse merger that takes the private company public. The deal was announced on Dec 23, 2024 and closed on Jul 25, 2025. The combined company trades as ImageneBio, Inc. (IMA) on Nasdaq.
ImageneBio, Inc. is a clinical-stage company developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life, with clinical data in atopic dermatitis and potential in other immunology indications.
- Status
- Completed
- Private company
- Inmagene Biopharmaceuticals
- Public company
- Ikena Oncology, Inc. (IKNA)
- Public company business before
- Nasdaq-listed oncology biotech seeking a strategic partner
- Announced
- Dec 23, 2024
- Closed
- Jul 25, 2025
- Combined company
- ImageneBio, Inc. (IMA)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Contingent value rights (CVR)
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Jul 29, 2025
- Closing exhibit
- Announcement 8-K Dec 23, 2024
- Announcement exhibit
- All filings on EDGAR CIK 1835579
Other completed reverse mergers
- Mechanics Bankinto HomeStreet, Inc. · Sep 2, 2025
- Rhino Digital Inc.into Phoenix Plus Corp. · Aug 19, 2025
- Nakamoto Holdings Inc.into Kindly MD, Inc. · Aug 14, 2025
- Abundia Global Impact Group, LLCinto Houston American Energy Corp. · Jul 1, 2025
- LNHC, Inc. (Ligand Pharmaceuticals subsidiary)into Channel Therapeutics Corporation · Jul 1, 2025
- Crescent Biopharma, Inc.into GlycoMimetics, Inc. · Jun 13, 2025